Cardiovascular Center, Steel Memorial Yawata Hospital, Japan.
Intern Med. 2022 Sep 15;61(18):2747-2751. doi: 10.2169/internalmedicine.9288-21. Epub 2022 Feb 19.
A 74-year-old man was admitted to our hospital to undergo radiofrequency catheter ablation (RFCA) of persistent atrial fibrillation (AF). We found that he had a history of heparin-induced thrombocytopenia (HIT). Thus, a direct thrombin inhibitor, Argatroban Hydrate (Argatroban), was used instead of heparin as anticoagulation therapy during the RFCA procedure. Finally, the AF was successfully treated by RFCA without any complications. Given these findings, the direct thrombin inhibitor Argatroban may be effective and feasible for anticoagulation therapy during RFCA procedures for AF in patients with HIT, such as the present case.
一位 74 岁男性因持续性心房颤动(房颤)到我院接受射频导管消融(RFCA)治疗。我们发现他有肝素诱导的血小板减少症(HIT)病史。因此,在 RFCA 过程中,我们使用直接凝血酶抑制剂阿加曲班(Argatroban)代替肝素进行抗凝治疗。最后,RFCA 成功治疗了房颤,没有任何并发症。鉴于这些发现,直接凝血酶抑制剂 Argatroban 可能对 HIT 患者的 RFCA 治疗中的抗凝治疗有效且可行,如本病例。